Evidence map›Paper›PMID 42558794›Full record

ReviewFrontiers in cell and developmental biology2026

Ferroptosis in liver diseases: molecular mechanisms, biomarker potential, and clinical translation.

Heng Tian, Yu Yang, Li Chen, Ran Wei, Wang Liu, Yuhan Liu, Jiaju Wang, Enba Zhuo, Kangsheng Gu, Jianwei Xing

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Heng Tian *Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yu Yang *Department of Oncology of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Li Chen *First Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
Ran Wei *First Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
Wang LiuDepartment of General Surgery, Sanya Central Hospital (The Third People's Hospital of Hainan Province), Sanya, Hainan, China.
Yuhan LiuFirst Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
Jiaju WangDepartment of Oncology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Enba ZhuoDepartment of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
Kangsheng GuDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Jianwei XingDepartment of General Surgery, Sanya Central Hospital (The Third People's Hospital of Hainan Province), Sanya, Hainan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is a type of intracellular, iron-dependent cell death that differs from apoptosis, necrosis, and autophagy. Ferroptosis is characterized by excessive lipid peroxidation. Iron-dependent, non-apoptotic cell death is linked to several liver diseases. Although numerous ferroptosis-associated genes and pathways have been linked to liver disorders, the exact mechanisms by which ferroptosis contributes to disease initiation and progression remain incompletely understood. In this review, we discuss the initiation and role of ferroptosis in the pathophysiology of liver diseases, including acute liver injury, liver fibrosis, hepatocellular carcinoma, viral hepatitis, autoimmune hepatitis, alcohol-associated liver disease, and NAFLD/MASLD. We first describe the regulatory function of ferroptosis before highlighting its relevance and underlying processes in several distinct liver disorders. In addition, we briefly discuss the potential clinical relevance of ferroptosis-related molecules and pathways as candidate biomarkers and therapeutic targets in liver diseases, with emphasis on their possible value in biomarker discovery, patient stratification, disease evaluation, and clinical translation. We also emphasize the context-dependent role of ferroptosis, in which its induction may be therapeutically beneficial in hepatocellular carcinoma or activated hepatic stellate cells, whereas excessive hepatocyte ferroptosis may aggravate non-malignant liver injury.

Indexed as

biomarkersclinical translationferroptosisliver diseasesprecision medicine

Identifiers

PMID42558794
PMCPMC13438154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.